In TAVAREC, there was no significant difference in survival between patients harbouring IDH1R132H and non-R132H IDH1/2-mutated tumours (HR 1.21, 95% CI [0.60, 2.45], p = 0.60). Here, IDH1 is linked to neoplasm.